Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021
Kristina L. Bajema, Rebecca M. Dahl, Mila M. Prill, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 37, pp. 1294-1299
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1641
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 416
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, et al.
Science Immunology (2022) Vol. 7, Iss. 69
Open Access | Times Cited: 404
Covid-19 Vaccine Effectiveness in New York State
Eli S. Rosenberg, Vajeera Dorabawila, Delia Easton, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 2, pp. 116-127
Open Access | Times Cited: 300
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
BMJ (2021), pp. e068848-e068848
Open Access | Times Cited: 222
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Fiona P. Havers, Huong Pham, Christopher A. Taylor, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 10, pp. 1071-1071
Open Access | Times Cited: 150
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
Sachin P. Gadani, Maria Reyes‐Mantilla, Larissa Jank, et al.
EBioMedicine (2021) Vol. 73, pp. 103636-103636
Open Access | Times Cited: 102
Adaptive Immune Responses and Immunity to SARS-CoV-2
Dragan Primorac, Kristijan Vrdoljak, Petar Brlek, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 90
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2022) Vol. 16, Iss. 2, pp. 102396-102396
Open Access | Times Cited: 89
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021
Kristina L. Bajema, Rebecca M. Dahl, Steve L. Evener, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 49, pp. 1700-1705
Open Access | Times Cited: 83
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Piotr Rzymski, Carlos A. Camargo, Andrzej Fal, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1299-1299
Open Access | Times Cited: 76
Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show
Owen Dyer
BMJ (2021), pp. n2282-n2282
Closed Access | Times Cited: 64
Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines
J. Daniel Kelly, Samuel Leonard, Katherine J. Hoggatt, et al.
JAMA (2022) Vol. 328, Iss. 14, pp. 1427-1427
Open Access | Times Cited: 60
Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies
Sodiq Ayobami Hameed, Stéphane Paul, Giann Kerwin Y. Dellosa, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 40
SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
Marianna Karachaliou, Gemma Moncunill, Ana Espinosa, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 38
Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system
George N. Ioannou, Emily R. Locke, Pamela K. Green, et al.
EClinicalMedicine (2022) Vol. 45, pp. 101326-101326
Open Access | Times Cited: 37
COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System
George N. Ioannou, Emily R. Locke, Ann M. O’Hare, et al.
Annals of Internal Medicine (2021) Vol. 175, Iss. 3, pp. 352-361
Open Access | Times Cited: 51
Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign
Theodore Lytras, Flora Kontopidou, Angeliki Lambrou, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 10, pp. 5044-5050
Open Access | Times Cited: 34
Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective
Chunlan Zhuang, Xiaohui Liu, Qi Chen, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 33
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis
Sara Sadeghi, Yasamin Kalantari, Sima Shokri, et al.
Journal of Clinical Virology (2022) Vol. 153, pp. 105196-105196
Open Access | Times Cited: 32
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Etsuro Nanishi, Ofer Levy, Al Ozonoff
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 29
COVID-19 Vaccination and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in the European Economic Area during Autumn 2021 Wave of SARS-CoV-2
Dominika Sikora, Piotr Rzymski
Vaccines (2022) Vol. 10, Iss. 3, pp. 437-437
Open Access | Times Cited: 27
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case–control study among US veterans
Yinong Young‐Xu, Gabrielle Zwain, Héctor S. Izurieta, et al.
BMJ Open (2022) Vol. 12, Iss. 8, pp. e063935-e063935
Open Access | Times Cited: 27
mRNA vaccines against respiratory viruses
Jennifer A. Whitaker, Hana M. El Sahly, C. Mary Healy
Current Opinion in Infectious Diseases (2023) Vol. 36, Iss. 5, pp. 385-393
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top